Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | PLG | P00747 | 2/20 | 0.36 |
| ▸ | F10 | P00742 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 6/20 | 0.34 |
| ▸ | BCHE | P06276 | 7/20 | 0.33 |
| ▸ | ACHE | P22303 | 7/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.32 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429634 | 0.94 | F2 (0.38) | F2PLGF10PLAUKLKB1 | |
| SCHEMBL4993349 | 0.93 | F2 (0.37) | F2PLGF10PLAUKLKB1 | |
| SCHEMBL4989553 | 0.90 | PLG (0.38) | F2PLGF10PLAUKLKB1 | |
| SCHEMBL4994776 | 0.90 | PLG (0.40) | F2PLGF10PLAUKLKB1 | |
| SCHEMBL4439721 | 0.90 | PLG (0.40) | F2PLGF10PLAUKLKB1 | |
| SCHEMBL4439634 | 0.90 | PLG (0.38) | F2PLGF10PLAUKLKB1 | |
| SCHEMBL4995396 | 0.89 | PLG (0.40) | F2PLGF10PLAUKLKB1 | |
| SCHEMBL4993681 | 0.89 | PLG (0.37) | F2PLGF10PLAUKLKB1 | |
| SCHEMBL4992945 | 0.89 | PLG (0.38) | F2PLGF10PLAUKLKB1 | |
| SCHEMBL4430980 | 0.89 | C3AR1 (0.35) | F2PLGF10PLAUKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125739-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | ENCYSIVE PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2008079371-A1 | MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF | ENCYSIVE PHARMACEUTICALS, INC. (US) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188528-A1 | Modulators of C3a receptor and methods of use thereof | C3AR1, C5, C5AR1 | F2 165/4885PLG 52/4885F10 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.